Title |
Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
|
---|---|
Published in |
American Journal of Hematology, August 2018
|
DOI | 10.1002/ajh.25154 |
Pubmed ID | |
Authors |
Cédric Rossi, Julia Gilhodes, Marie Maerevoet, Charles Herbaux, Franck Morschhauser, Pauline Brice, Sylvain Garciaz, Cécile Borel, Loïc Ysebaert, Lucie Obéric, Julien Lazarovici, Bénédicte Deau, Jehan Dupuis, Adrien Chauchet, Julie Abraham, Fontanet Bijou, Aspasia Stamatoullas‐Bastard, Jean‐Valère Malfuson, Camille Golfier, Camille Laurent, Sarah Pericart, Alexandra Traverse‐Glehen, Salim Kanoun, Thomas Filleron, René‐Olivier Casasnovas, Hervé Ghesquières |
Abstract |
Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pre-treated before anti-PD-1 (70% received ASCT and 93% BV). Unsatisfactory responses to anti-PD1 therapy were progressive disease (PD) (n=24) and partial response (PR) (n=6). For the 24 PD patients, median anti-PD-1 related PFS was 7.5 months (95%CI, 5.7-11.6); 17 received subsequent CT alone (Group 1) and 7 received CT in addition to anti-PD-1 (Group 2). 16/24 patients (67%) obtained an objective response. In the 15 patients treated with the same CT, twelve obtained PR or complete response (CR). In Group 1, there were 7 CR (41%), 3 PR (18%), and 7 PD (41%). In Group 2, there were 4 CR (57%), 2 PR (29%), and 1 SD (14%). No unexpected toxicity was observed. Six patients who achieved response proceeded to allogeneic SCT. With a median follow-up of 12.1 months (7-14.7), the median PFS following the initiation of CT was 11 months (95%CI, 6.3; not reached) and the median of overall survival was not reached. These observations in highly pre-treated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT. This article is protected by copyright. All rights reserved. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 22% |
France | 1 | 11% |
Spain | 1 | 11% |
Unknown | 5 | 56% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 8 | 89% |
Science communicators (journalists, bloggers, editors) | 1 | 11% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
Unknown | 61 | 100% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Researcher | 10 | 16% |
Other | 9 | 15% |
Student > Postgraduate | 6 | 10% |
Student > Ph. D. Student | 4 | 7% |
Student > Doctoral Student | 3 | 5% |
Other | 7 | 11% |
Unknown | 22 | 36% |
Readers by discipline | Count | As % |
---|---|---|
Medicine and Dentistry | 30 | 49% |
Nursing and Health Professions | 2 | 3% |
Biochemistry, Genetics and Molecular Biology | 2 | 3% |
Physics and Astronomy | 1 | 2% |
Immunology and Microbiology | 1 | 2% |
Other | 0 | 0% |
Unknown | 25 | 41% |